MASTL Promotes Hepatocellular Carcinoma Progression and Paclitaxel Resistance Through Mitotic Catastrophe
Cancer Science · 2026
DOI: 10.1111/cas.70287 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Ke Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Drug Resistance, Neoplasm, Paclitaxel. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Health Commission of Chongqing's First Batch of Key Public Health Disciplines, Chongqing Natural Science Foundation, Joint Project of the Pinnacle Disciplinary Group at the Second Affiliated Hospital of Chongqing Medical University.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with limited therapeutic options. Microtubule‐associated serine/threonine kinase‐like ( MASTL ), a pivotal regulator of mitosis, remains poorly characterized in HCC. This study aimed to elucidate the clinical significance, biological functions, and molecular mechanisms of MASTL in HCC progression. Bioinformatics analysis of TCGA and ICGC datasets revealed MASTL overexpression correlated with advanced tumor stage and served as an independent prognostic factor. Functional studies demonstrated that MASTL knockdown significantly disrupts HCC cell proliferation, increases the incidence of abnormal mitotic events, and amplifies DNA damage, collectively driving mitotic catastrophe (MC) and subsequent cell death. Mechanistically, MASTL regulated paclitaxel sensitivity by modulating ENSA phosphorylation and PP2A‐B55α activity, with PP2A‐B55α knockdown reversing MASTL deficiency‐induced MC. Transcriptional regulation analysis identified E2F1 as a direct activator of MASTL expression, confirmed by ChIP‐qPCR and dual‐luciferase reporter assays. These findings establish MASTL as a critical oncogene in HCC through the E2F1‐MASTL‐PP2A‐B55α axis, suggesting its potential as both a prognostic biomarker and therapeutic target for HCC. Future studies should explore MASTL inhibitors in combination with conventional chemotherapy to overcome drug resistance in HCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongq…
ORCID-Profile: Qiang Luo
Förderung
- Health Commission of Chongqing's First Batch of Key Public Health Disciplines
- Chongqing Natural Science Foundation
- Joint Project of the Pinnacle Disciplinary Group at the Second Affiliated Hospital of Chongqing Medical University
Zitieren
APA
Wang, K., Fu, Z., Xiong, C., Zhang, J., & Luo, Q. (2026). MASTL Promotes Hepatocellular Carcinoma Progression and Paclitaxel Resistance Through Mitotic Catastrophe. Cancer Science. https://doi.org/10.1111/cas.70287
Vancouver
Wang K, Fu Z, Xiong C, Zhang J, Luo Q. MASTL Promotes Hepatocellular Carcinoma Progression and Paclitaxel Resistance Through Mitotic Catastrophe. Cancer Science. 2026. doi:10.1111/cas.70287
BibTeX
@article{Wang2026,
author = {Wang, Ke and Fu, Ziwei and Xiong, Chuan and Zhang, Jing and Luo, Qiang},
title = {MASTL Promotes Hepatocellular Carcinoma Progression and Paclitaxel Resistance Through Mitotic Catastrophe},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70287}
}
EUVIMED